Cargando…
The Clinical and Histopathological Feature of Renal Manifestation of TAFRO Syndrome
INTRODUCTION: Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly (TAFRO) syndrome is a severe subtype of idiopathic multicentric Castleman’s disease, characterized by thrombocytopenia, anasarca, fever, reticulin myelofibrosis, and organomegaly. Renal complication of this...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403508/ https://www.ncbi.nlm.nih.gov/pubmed/32775816 http://dx.doi.org/10.1016/j.ekir.2020.05.004 |
_version_ | 1783566956184469504 |
---|---|
author | Mizuno, Hiroki Sawa, Naoki Watanabe, Shun Ikuma, Daisuke Sekine, Akinari Kawada, Masahiro Yamanouchi, Masayuki Hasegawa, Eiko Suwabe, Tatsuya Hoshino, Junichi Takaichi, Kenmei Kinowaki, Keiichi Fujii, Takeshi Ohashi, Kenichi Nagata, Michio Yamaguchi, Yutaka Ubara, Yoshifumi |
author_facet | Mizuno, Hiroki Sawa, Naoki Watanabe, Shun Ikuma, Daisuke Sekine, Akinari Kawada, Masahiro Yamanouchi, Masayuki Hasegawa, Eiko Suwabe, Tatsuya Hoshino, Junichi Takaichi, Kenmei Kinowaki, Keiichi Fujii, Takeshi Ohashi, Kenichi Nagata, Michio Yamaguchi, Yutaka Ubara, Yoshifumi |
author_sort | Mizuno, Hiroki |
collection | PubMed |
description | INTRODUCTION: Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly (TAFRO) syndrome is a severe subtype of idiopathic multicentric Castleman’s disease, characterized by thrombocytopenia, anasarca, fever, reticulin myelofibrosis, and organomegaly. Renal complication of this disease can be life-threatening and sometimes requires hemodialysis, but it has not been elucidated in detail. METHODS: Case-series was designed to evaluate the renal histology of patients with TAFRO syndrome treated at our hospital. RESULTS: Seven patients were eligible to the criteria. All of them had severe diuretic-resistant anasarca and 6 of 7 had mild proteinuria (<1 g daily). On light microscopy, all patients showed glomerular endotheliopathy characterized by endothelial cell swelling and a double contour of the glomerular basement membrane with mesangiolysis or mesangial loosening. Immunofluorescent staining and electron microscopy did not detect immune deposits in any patient. Electron microscopy revealed endothelial cell swelling with diffuse expansion of the subendothelial space, loss of mesangial architecture, and loss of endothelial cell fenestrations. Treatment with glucocorticoids and molecular-targeting agents, including tocilizumab and rituximab, improved renal dysfunction and anasarca. In 4 of 7 patients with persistent thrombocytopenia, hemorrhagic events occurred despite platelet transfusion or thrombopoietin receptor antagonist therapy. CONCLUSION: Severe diuretic-resistant anasarca with mild proteinuria and severe glomerular endotheliopathy were common characteristics of renal dysfunction due to TAFRO syndrome. In addition, endothelial changes mediated via interleukin (IL)-6 and vascular endothelial growth factor (VEGF) that lead to vascular hyperpermeability and water leakage might contribute to anasarca, because molecular-targeting therapy directed against IL-6 or VEGF improved renal dysfunction and severe endothelial damage. |
format | Online Article Text |
id | pubmed-7403508 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-74035082020-08-06 The Clinical and Histopathological Feature of Renal Manifestation of TAFRO Syndrome Mizuno, Hiroki Sawa, Naoki Watanabe, Shun Ikuma, Daisuke Sekine, Akinari Kawada, Masahiro Yamanouchi, Masayuki Hasegawa, Eiko Suwabe, Tatsuya Hoshino, Junichi Takaichi, Kenmei Kinowaki, Keiichi Fujii, Takeshi Ohashi, Kenichi Nagata, Michio Yamaguchi, Yutaka Ubara, Yoshifumi Kidney Int Rep Clinical Research INTRODUCTION: Thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly (TAFRO) syndrome is a severe subtype of idiopathic multicentric Castleman’s disease, characterized by thrombocytopenia, anasarca, fever, reticulin myelofibrosis, and organomegaly. Renal complication of this disease can be life-threatening and sometimes requires hemodialysis, but it has not been elucidated in detail. METHODS: Case-series was designed to evaluate the renal histology of patients with TAFRO syndrome treated at our hospital. RESULTS: Seven patients were eligible to the criteria. All of them had severe diuretic-resistant anasarca and 6 of 7 had mild proteinuria (<1 g daily). On light microscopy, all patients showed glomerular endotheliopathy characterized by endothelial cell swelling and a double contour of the glomerular basement membrane with mesangiolysis or mesangial loosening. Immunofluorescent staining and electron microscopy did not detect immune deposits in any patient. Electron microscopy revealed endothelial cell swelling with diffuse expansion of the subendothelial space, loss of mesangial architecture, and loss of endothelial cell fenestrations. Treatment with glucocorticoids and molecular-targeting agents, including tocilizumab and rituximab, improved renal dysfunction and anasarca. In 4 of 7 patients with persistent thrombocytopenia, hemorrhagic events occurred despite platelet transfusion or thrombopoietin receptor antagonist therapy. CONCLUSION: Severe diuretic-resistant anasarca with mild proteinuria and severe glomerular endotheliopathy were common characteristics of renal dysfunction due to TAFRO syndrome. In addition, endothelial changes mediated via interleukin (IL)-6 and vascular endothelial growth factor (VEGF) that lead to vascular hyperpermeability and water leakage might contribute to anasarca, because molecular-targeting therapy directed against IL-6 or VEGF improved renal dysfunction and severe endothelial damage. Elsevier 2020-05-19 /pmc/articles/PMC7403508/ /pubmed/32775816 http://dx.doi.org/10.1016/j.ekir.2020.05.004 Text en © 2020 International Society of Nephrology. Published by Elsevier Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Clinical Research Mizuno, Hiroki Sawa, Naoki Watanabe, Shun Ikuma, Daisuke Sekine, Akinari Kawada, Masahiro Yamanouchi, Masayuki Hasegawa, Eiko Suwabe, Tatsuya Hoshino, Junichi Takaichi, Kenmei Kinowaki, Keiichi Fujii, Takeshi Ohashi, Kenichi Nagata, Michio Yamaguchi, Yutaka Ubara, Yoshifumi The Clinical and Histopathological Feature of Renal Manifestation of TAFRO Syndrome |
title | The Clinical and Histopathological Feature of Renal Manifestation of TAFRO Syndrome |
title_full | The Clinical and Histopathological Feature of Renal Manifestation of TAFRO Syndrome |
title_fullStr | The Clinical and Histopathological Feature of Renal Manifestation of TAFRO Syndrome |
title_full_unstemmed | The Clinical and Histopathological Feature of Renal Manifestation of TAFRO Syndrome |
title_short | The Clinical and Histopathological Feature of Renal Manifestation of TAFRO Syndrome |
title_sort | clinical and histopathological feature of renal manifestation of tafro syndrome |
topic | Clinical Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403508/ https://www.ncbi.nlm.nih.gov/pubmed/32775816 http://dx.doi.org/10.1016/j.ekir.2020.05.004 |
work_keys_str_mv | AT mizunohiroki theclinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome AT sawanaoki theclinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome AT watanabeshun theclinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome AT ikumadaisuke theclinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome AT sekineakinari theclinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome AT kawadamasahiro theclinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome AT yamanouchimasayuki theclinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome AT hasegawaeiko theclinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome AT suwabetatsuya theclinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome AT hoshinojunichi theclinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome AT takaichikenmei theclinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome AT kinowakikeiichi theclinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome AT fujiitakeshi theclinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome AT ohashikenichi theclinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome AT nagatamichio theclinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome AT yamaguchiyutaka theclinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome AT ubarayoshifumi theclinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome AT mizunohiroki clinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome AT sawanaoki clinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome AT watanabeshun clinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome AT ikumadaisuke clinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome AT sekineakinari clinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome AT kawadamasahiro clinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome AT yamanouchimasayuki clinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome AT hasegawaeiko clinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome AT suwabetatsuya clinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome AT hoshinojunichi clinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome AT takaichikenmei clinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome AT kinowakikeiichi clinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome AT fujiitakeshi clinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome AT ohashikenichi clinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome AT nagatamichio clinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome AT yamaguchiyutaka clinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome AT ubarayoshifumi clinicalandhistopathologicalfeatureofrenalmanifestationoftafrosyndrome |